+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease Therapeutics Market Research Report by Drug Class, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4989588
  • Report
  • April 2022
  • Region: Global
  • 187 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbott Laboratories
  • Adamis Laboratories, Inc.
  • Almirall
  • Astellas Pharma
  • AstraZeneca Plc
  • Mylan N.V.
The Global Chronic Obstructive Pulmonary Disease Therapeutics Market size was estimated at USD 17.68 billion in 2021, USD 18.93 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.28% to reach USD 26.95 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Chronic Obstructive Pulmonary Disease Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Bronchodilators, Combination, Corticosteroids, Mucokinetics, and Phosphodiesterase Type 4 Inhibitors.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Chronic Obstructive Pulmonary Disease Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Chronic Obstructive Pulmonary Disease Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market, including Abbott Laboratories, Adamis Laboratories, Inc., Almirall, Astellas Pharma, AstraZeneca Plc, Boehringer Ingelheim Pharmaceuticals, Inc., Mylan N.V., Novartis AG, Orion Corporation., Pfizer Inc., Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Chronic Obstructive Pulmonary Disease Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?
6. What is the market share of the leading vendors in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?
Frequently Asked Questions about the Global Chronic Obstructive Pulmonary Disease Therapeutics Market

What is the estimated value of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

The Global Chronic Obstructive Pulmonary Disease Therapeutics Market was estimated to be valued at $17.7 Billion in 2021.

What is the growth rate of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

The growth rate of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market is 7.2%, with an estimated value of $27.0 Billion by 2027.

What is the forecasted size of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

The Global Chronic Obstructive Pulmonary Disease Therapeutics Market is estimated to be worth $27.0 Billion by 2027.

Who are the key companies in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

Key companies in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market include Abbott Laboratories, Adamis Laboratories, Inc., Almirall, Astellas Pharma, AstraZeneca Plc, Boehringer Ingelheim Pharmaceuticals, Inc., Mylan N.V., Novartis AG and Pfizer Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Adamis Laboratories, Inc.
  • Almirall
  • Astellas Pharma
  • AstraZeneca Plc
  • Mylan N.V.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of asthma patients
5.1.1.2. Growing cases of chronic respiratory diseases
5.1.1.3. Surge in demand for home care therapeutic devices
5.1.2. Restraints
5.1.2.1. Adverse effect associated with the treatment
5.1.3. Opportunities
5.1.3.1. Growing innovation in the treatment of asthma and technological advancement in the asthma devices
5.1.3.2. Rise in the number of product launches
5.1.4. Challenges
5.1.4.1. Strict rules and regulations imposed by the government
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Bronchodilators
6.3. Combination
6.4. Corticosteroids
6.5. Mucokinetics
6.6. Phosphodiesterase Type 4 Inhibitors
7. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies
8. Americas Chronic Obstructive Pulmonary Disease Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. Adamis Laboratories, Inc.
12.3. Almirall
12.4. Astellas Pharma
12.5. AstraZeneca Plc
12.6. Boehringer Ingelheim Pharmaceuticals, Inc.
12.7. Mylan N.V.
12.8. Novartis AG
12.9. Orion Corporation.
12.10. Pfizer Inc.
12.11. Sunovion Pharmaceuticals, Inc.
12.12. Teva Pharmaceutical Industries Ltd
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: DYNAMICS
FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD BILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 24. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 25. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 26. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 27. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 28. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 29. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 30. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 31. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 32. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 33. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 34. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 55. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 56. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 25. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 27. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 36. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 38. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 41. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 43. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 46. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 47. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 48. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 49. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 51. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 52. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 53. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 54. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 55. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 56. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 57. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 58. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 59. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 60. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 61. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 62. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 66. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 71. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: SCORES
TABLE 76. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 77. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 78. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: RANKING
TABLE 79. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 80. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 81. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 82. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 83. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 84. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 85. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Adamis Laboratories, Inc.
  • Almirall
  • Astellas Pharma
  • AstraZeneca Plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation.
  • Pfizer Inc.
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...